Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years.
• The salient findings indicate that drug mix effect (switching cheaper to expensive drugs and vice versa) rather than quantity increase was the main factor for the growth of overall drug spending between 2006 and 2010. Furthermore, the effects of new drugs were minimal, compared to those of existing drugs although they positively affected on the growth of drug spending.
• Consequently, it is time to rethink pharmaceutical cost containment policy more focusing on rational use of drugs.
Background
Pharmaceutical expenditure in South Korea is of particular interest to healthcare system regulators. Over the last decade, pharmaceutical expenditure in Korea increased 3.05 fold, while total health expenditure increased 2.45 fold [1] . South Korea spent 21.6% of its total healthcare expenditure on pharmaceuticals in 2010 [1] . This compares to Organization for Economic Cooperation and Development (OECD) countries, which spent approximately 18-19% in 2009 [2] .
However, in 2010 pharmaceutical expenditure actually fell in 2010 among some EU member states [3] . This may be due to a variety of reforms and initiatives including stricter regulations for granting premium prices for new drugs and managing their entry, compulsory price cuts for existing drugs as well as a range of demand-side measures to enhance the prescribing of low cost generics versus premium priced patented products in a class or related class [4] [5] [6] [7] [8] . Aging populations, the increased prevalence of chronic diseases, early adoption of expensive new drugs, and doctors' preference for prescribing high-cost drugs are often cited as explanations for the growth of pharmaceutical expenditure in Korea [9] [10] . This is set to continue with the policy to expand National Health Insurance (NHI) coverage for four disease areas including cerebrovascular and cardiovascular disease, rare diseases and cancer, which has been initiated by new ruling government, drug expenditure [11] .
Understanding which factors contribute to increased pharmaceutical expenditure is important to the Ministry of Health and Welfare (MOHW) and the National Health Insurance Service (NHIS), which are responsible for the financial management of national health insurance. A decomposition analysis is often used to identify factors that contribute to the increase in drug spending. Drug expenditure is usually broken down into price, quantity, and drug mix using an index method, such as Lasyperes, Paasches and Fisher's Ideal [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . However, this methodology has been criticized because it could not show the contribution of new drugs to the growth of drug spending on each component of drug spending [24] [25] [26] . New drugs are usually more expensive than incumbents (existing drugs) and are consequently considered one of key drivers of increases in pharmaceutical expenditure [4, [26] [27] . Switching from cheaper to more expensive drugs, the so-called "drug mix effect" is one of the effects induced by the introduction of new drugs. Unless demand-side measures are in place, new premium priced drugs could replace cheaper incumbents, increasing the cost of treatment. New drugs can also induce demand from those who could not be treated appropriately with existing drug therapies, also referred to as the "treatment expansion effect" [24, [26] [27] [28] .
In this study, we adopted a modified model of the decomposition analysis to assess the impact of new and the established drugs on the dynamics of drug cost, and to identify policy implications for drug cost containment. Our analytical approach followed on from the model of Gerdtham and colleagues [20] [21] [22] and Addis and Magrini [23] , but we aim to quantify drug mix effect and treatment expansion effect of both new and existing drugs, respectively. The remainder of this article is organized as follows: an overview of the Korean pharmaceutical market and the introduction of new drugs; limitations of the decomposition analysis that has been applied in previous studies; details of our approach applied in this study; and ending with conclusions drawn from our analysis.
The Korean pharmaceutical market and the introduction of new drugs
Drug expenditure in Korea has grown steeply following the implementation of the Separation of Drug Dispensing and Prescribing (SDP) policy in 2000 [ Figure 1 ]. The market size for pharmaceuticals in 2011 was 16,402 trillion Korean Won (KRW) (USD 14.325 billion) and pharmaceutical expenditure by National Health Insurance (NHI) amounted to 81.9% of the total market [29] . Most medicines available on the market were consumed under the NHI scheme, although the number of reimbursable drugs accounted for only 36.8% of all drugs approved by 
Limitations of previous decomposition studies
Several studies have analyzed drug expenditure by separating it into constituent elements, including price and quantity [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Gerdtham and colleagues [20] [21] [22] examined total drug expenditure in Sweden, emphasized the importance of residual (in other words, "drug mix").
Without changing price and quantity, drug costs can increase as a result of switching from a cheaper drug to an expensive one in a class or related class; this is the so-called "drug mix" effect.
They pointed out that standard price indices do not reflect price changes resulting from changes in drug consumption, especially changes resulting from the introduction of new drugs. Several studies have examined drug mix effect and identified it as major factor in drug spending growth [20] [21] [22] [23] [24] . Dubois and colleagues [25] tried to quantify the impact of new drugs by calculating price and volume factors including changes in average price per day, the number of prescriptions per person, and the number of days per prescription. Their results indicate that prescribed days, prescriptions, and the number of patients were significant factors in expenditure growth.
According to Gerdtham and colleagues' model [20] [21] [22] , drug mix (residual) and treatment expansion effect (quantity increase) were measured. These effects were attributable to both new and existing drugs. However, previous studies didn't distinguish these effects according to types of drugs. In this study, we tried to quantify the impact of new drugs on the components of drug cost.
To do so, we proposed a modified formula to segregate drug mix and treatment expansion effects by types of drugs: new and existing drugs. We then applied this formula to investigate the factors contributing to increased drug expenditure in the period from 2006 to 2010 in South Korea, and quantified the effects of new and existing drugs on changes in each component of drug cost.
Finally, we have made some suggestions for the authorities to consider when deliberating future reforms. These are based on activities successfully undertaken by European health authorities and health insurance agencies.
Materials and Method

Data collection
The data used in this study were obtained from the National Health Insurance Service (NHIS), which covers about 97% of Korean population. Total pharmaceutical expenditure data from NHIS claims for the years from 2006 to 2010 were used. Over 12,000 reimbursable products (about 4,000 ingredients) were included for analysis. Each ingredient identified in the NHIS data was matched to the Anatomical Therapeutic Classification (ATC) code [33] . The data were compiled based on ingredients. Medicines that incurred no charges in 2006, but appeared in the data in 2010 were regarded as new drugs. All other listed drugs were considered incumbents. Quantity data was collected as the minimum unit for each drug and delivery system, e.g. ampoules, tablets, patches, inhalers and capsules, as it proved impossible to calculate all utilisation in terms of defined daily doses.
Study methodology
The equation (Equation 1), first proposed by Gerdtham and colleagues [20] [21] [22] shows changes in price (P), quantity (Q) and drug mix (ε). The price change (P) is calculated by Laspeyres index.
According to this index, the price of new drugs is not detected because their prices are not available at the base period. Thus, Laspeyres index (P) reflects only the price of incumbents only.
The quantity ratio (Q) shows changes in the quantities of prescribed drugs including both new and incumbent drugs. Drug mix (ε) indicates changes in the weighted average cost of drugs attributable to both new and existing ones. Thus, quantity change and drug mix are attributable to both new and existing drugs. Consequently, we can measure drug mix and treatment expansion effects due to new drugs and existing drugs, separately. This is different to the general belief that new drugs are generally regarded as a key driver of increased drug expenditure. Table 2 presents the results according to ATC codes. Drug spending has risen most significantly in the "sensory organs" class of drugs ( =1.78), followed by the "various" class ( =1.68).
Results
Increases in expenditure for the various class (V), sensory organs(S), anti-neoplastics & immune modulating agents (L), blood and blood forming organs(B), cardiovascular system(C), nervous system(N) and respiratory system(R) were greater than the average growth rate (1.42). Growth of expenditure for all groups was mainly attributed to incumbent drugs. New drugs influenced expenditure most greatly for the "sensory organs" class ( =1.13). No new drugs were launched during the observation period for class P (anti-parasitics, insecticides, and repellents). Although drug spending for class C drugs increased by 1.53 fold, they represented the greatest percentage of total drug spending. A breakdown of drug expenditure factors for each ATC group, and each type of drug, is presented in Table 3 . Price indices for all classes are less than 1, indicating a decrease in the prices of existing drugs. A major factor in total drug expenditure growth was increased quantities for all classes except ATC classes A, J, M, N and R, for which the drug mix effect was a more significant factor. Drug mix for all classes increased ( >1) except for class P ( =0.86). The effects of new drugs equalled 1 for ATC class P. This indicates that cheaper drugs in ATC class P were used instead of expensive ones, without the introduction of new drugs. For ATC class S, cheaper existing drugs replaced more expensive ones ( =0.96), but the quantity ( ) increased substantially (1.88 times). New drugs within this class, which were more expensive than incumbents, were introduced and prescribed ( =1.09), which led to the increase in overall drug expenditure. Cheaper anti-parasitic drugs were increasingly used ( =0.86) without the introduction of new drugs. For ATC class S, drug quantities substantially increased ( =1.88) and cheaper existing drugs were frequently used ( =0.96). In addition, expensive new drugs were introduced ( =1.03 and =1.02). Overall, these factors contributed to an increase in drug spending. [20] [21] [22] [23] [24] considered only changes in price, quantity, and drug mix over time, without segregating observed changes by type of drug. However, these changes were attributable to both new drugs and existing drugs. Our research question was posed to distinguish the effects associated with new and existing drugs.
The previous model of Gerdtham and colleagues [20] [21] [22] was modified to calculate the treatment expansion effect ( ) and drug-mix effect ( ). The equation (Equation 3 ) was also designed to measure the impact of existing drugs in light of changes in price ( , quantity ( ) and drug mix ( ).
The results of this study indicate that existing drugs had a greater effect on the growth of drug expenditure in recent years in Korea than the launch of new premium priced drugs. Although treatment expansion and the drug-mix effect of new drugs positively contributed to the increase in drug spending, the quantified impact was minimal. Existing drugs substantially contributed to increased pharmaceutical expenditure in recent years. Prices for existing drugs decreased slightly over the period ( =0.86), but the drug-mix effect ( =1.32) had the most significant impact, followed by quantity increase ( =1.26). Given that increased drug volumes have long been claimed to be the major factor contributing to the growth of Korean pharmaceutical expenditure in recent years [17] [18] [19] , this study presents different results. Our findings indicate that the drug-mix effect, both for existing and new drugs, had a greater impact on the growth of drug expenditure than increased volumes. Additionally, the growth of expenditure was mainly attributable to existing drugs rather than new drugs. Prices for existing drugs decreased in 2010 in all ATC classes when compared to 2006 prices. However, the overall drug-mix changed in a number of classes increasing overall drug expenditure. The drug mix effect was more significant for ATC classes A, J, M, N and R, with increasing volumes the major factor for increased drug expenditure in the other classes. This is perhaps not surprising since cost containment measures for pharmaceuticals in South Korea have traditionally focused on enforced price cuts rather than demand-side measures. Numerous re-pricing strategies have been implemented, but the price decreases over the 5 years have not been significant [32, [34] [35] . The absence of policies that encourage the use of cheaper drugs or more cost-effective prescriptive practices results in the increase utilization of expensive drugs facilitated by the considerable marketing activities of pharmaceutical companies [36] . Therefore, demand-side strategies to address this should be prioritized in order to efficiently control the increase of pharmaceutical expenditure in Korea with increased coverage in four disease areas.
Several policies enacted by the NHIS targeting new drugs, such as the PLS and price negotiation procedure with the single payer, have acted as an entry barrier. However, many of the strategies for drugs that are already listed have focused only on cutting prices, and the effectiveness of these strategies is debatable [37] . Since our findings suggest that existing drugs rather than new drugs have a significant impact on the growth of drug expenditure, policies targeting both cost-effective prescription practices and efficient price controls for existing drugs should be considered. There have been a number of supply-and demand-side measures across Europe to enhance the prescribing of low cost generics in classes where all the drugs are seen as similar in all or nearly all patients [38] [39] [40] [41] [42] . These initiatives have released considerable resources without compromised care (summarized in Table 4 ), with the products in these classes seen as therapeutically similar at appropriate doses demonstrated by meta analyses, registry studies as well as successful therapeutic switching programs [47] [48] [49] [50] [51] [52] [53] .
A similar finding regarding losartan in Sweden was seen in NHS Bury in England. Initially there was no change in the utilization of losartan post generics. This changed significantly following multiple interventions which were similar to Sweden (Table 4) for patients with hypertension, with losartan utilisation increasing significantly from 26% of all single ARBs to 65% 7 months later [49] .
The savings were estimated at eight times the cost of implementing this comprehensive program [49] . We accept there are limitations with the study design. These include our suggested methodology.
However, we believe this approach is justified for the reasons we have given. We also accept that we have not used defined daily doses in our analysis. However, other studies have used different units including IMS units [54] as well as items dispensed [49] . Consequently, we believe our findings are justified and provide direction to the authorities in Korea.
Conclusions
This study used a model to assess the impact of both new and existing drugs on changes in price, 
